Exai Bio Expands RNA-based Breast Cancer Liquid Biopsy Platform through Collaboration
Exai Bio is collaborating with Quantum Leap Healthcare Collaborative to broaden the use of its novel, RNA-based liquid biopsy platform.
Exai Bio is collaborating with Quantum Leap Healthcare Collaborative to broaden the use of its novel, RNA-based liquid biopsy platform.
Researchers released data demonstrating that an RNA-based liquid biopsy platform accurately detected breast cancer at the earliest stages.
More than two years after the COVID-19 pandemic began, cancer diagnoses continue to lag behind pre-pandemic levels.
The ASCO has expanded the utility of BCI in its guideline: “Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer.”
Read MoreThis study validated the clinical utility of a DCIS test to predict recurrence risk and radiation therapy benefit in certain patients
Read MoreProteins could one day allow breast cancer screenings to be done via blood test thanks to new biomarkers identified in breast milk.
Read MoreLiquid biopsy performed on serum samples from breast cancer patients can provide increasingly accurate information on cancer progression.
Read MorePaige, has launched its Paige Breast Lymph Node, an AI software that helps detect if breast cancer has metastasized to lymph nodes.
Read MorePrior to the new tool, inflammatory breast cancer lacked a formal, objective medical definition, and diagnosis was often delayed, misdiagnosed, or missed.
Read MoreNew research has found a connection between aggressive breast cancer cells and the dual CXCR4-CCR7 cell surface protein complexes.
Read MoreUsing current standard HER2 assays as a diagnostic test may result in a mis-assignment for treatment of breast cancer with a promising new drug.
Read MoreThe partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing.
Read MoreBioReference will use Gestalt Diagnostic’s Digital Pathology solution with Mindpeak’s AI cancer diagnostics algorithm for quantification of cancer cells.
Read MoreThe novel metastatic breast cancer test includes both cell-based and cell-free analysis from a single blood draw.
Read MoreA new assay can identify HER2 and other tumor alterations in the cerebrospinal fluid of patients with breast cancer and leptomeningeal disease (LMD).
Read MoreRoche will launch three new automated digital pathology algorithms, that will serve as important biomarkers for breast cancer patients.
Read MoreThe safe, painless diagnostic tool used to detect breast cancer uses a low electrical current instead of radiation.
Read MoreThe US Food and Drug Administration (FDA) has granted ‘Breakthrough Device Designation’ for Datar Cancer Genetics’ ‘TriNetra’ blood test for breast cancer.
Read More